Cardiovascular disease and dementia are growing medical and social problems in aging societies. Appropriate knowledge of cardiovascular disease and cognitive decline risk factors (RFs) are critical for global CVR health preventive intervention. Many epidemiological studies use case definition based on data collected/measured in a single visit, a fact that can overestimate prevalence rates and distant from clinical practice demanding criteria. Portugal displays an elevated stroke mortality rate. However, population's global CV risk characterization is limited, namely, considering traditional/nontraditional RF and new intermediate phenotypes of CV and renal disease. Association of hemodynamic variables (pulse wave velocity and central blood pressure) with global CVR stratification, cognitive performance, and kidney disease are practically inexistent at a dwelling population level.
Study Design and Methods
After reviewing published data, we designed a population-based cohort study to analyze the prevalence of these cardiovascular RFs and intermediate phenotypes, using random sampling of adult dwellers living in 2 adjacent cities. Strict definition of phenotypes was planned: subjects were observed twice, and several hemodynamic and other biological variables measured at least 3 months apart.
Results
Three thousand thirty-eight subjects were enrolled, and extensive data collection (including central and peripheral blood pressure, pulse wave velocity), sample processing, and biobank edification were carried out. One thousand forty-seven cognitive evaluations were performed.
Conclusions
Seeking for CV risk reclassification, early identification of subjects at risk, and evidence of early vascular aging and cognitive and renal function decline, using the strict daily clinical practice criteria, will lead to better resource allocation in preventive measures at a population level.
DzauVJ, AntmanEM, BlackHR, . The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part I: pathophysiology and clinical trial evidence (risk factors through stable coronary artery disease). Circulation. 2006; 114: 2850–2870.
2.
DzauVJ, AntmanEM, BlackHR, . The cardiovascular disease continuum validated: clinical evidence of improved patient outcomes: part II: clinical trial evidence (acute coronary syndromes through renal disease) and future directions. Circulation. 2006; 114: 2871–2891.
3.
O'RourkeMF, SafarME, DzauV. The cardiovascular continuum extended: aging effects on the aorta and microvasculature. Vasc Med. 2010; 15: 461–468.
4.
LozanoR, NaghaviM, ForemanK, . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013; 380: 2095–2128.
5.
ManciaG, de BackerG, DominiczakA, . 2007Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007; 25: 1105–1187.
6.
ConroyRM, PyoralaK, FitzgeraldAP, . Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003; 24: 987–1003.
7.
ReinerZ, CatapanoAL, deBacker G, . ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769–1818.
8.
Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012; 35 (suppl 1): S64–S71.
9.
K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43: S1–S290.
10.
PerkJ, de BackerG, GohlkeH, . European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2012; 33: 1635–1701.
11.
SantosNC, CostaPS, CunhaP, . Mood is a key determinant of cognitive performance in community-dwelling older adults: a cross-sectional analysis. Age (Dordr). 2013; 35: 1983–1993.
12.
KimAS, JohnstonSC.Global variation in the relative burden of stroke and ischemic heart disease. Circulation. 2011; 124: 314–323.
13.
CorreiaM, SilvaMR, MatosI, . Prospective community-based study of stroke in Northern Portugal: incidence and case fatality in rural and urban populations. Stroke. 2004; 35: 2048–2053.
14.
CorreiaM, SilvaMR, MagalhaesR, . Transient ischemic attacks in rural and urban northern Portugal: incidence and short-term prognosis. Stroke. 2006; 37: 50–55.
15.
Muller-NordhornJ, BintingS, RollS, . An update on regional variation in cardiovascular mortality within Europe. Eur Heart J. 2008; 29: 1316–1326.
16.
Ferreira-PintoLM, Rocha-GoncalvesF, Teixeira-PintoA. An ecological study on the geographic patterns of ischaemic heart disease in Portugal and its association with demography, economic factors and health resources distribution. BMJ Open. 2012; 2. pii:e000595.
17.
MacedoME, LimaMJ, SilvaAO, . Prevalence, awareness, treatment and control of hypertension in Portugal: the PAP study. J Hypertens. 2005; 23: 1661–1616.
18.
Cortez-DiasN, MartinsS, BeloA, . Prevalence and management of hypertension in primary care in Portugal. Insights from the VALSIM study. Rev Port Cardiol. 2009; 28: 499–523.
19.
de MacedoME, LimaMJ, SilvaAO, . Prevalence, awareness, treatment and control of hypertension in Portugal. The PAP study. Rev Port Cardiol. 2007; 26: 21–39.
20.
ClaraJG, de MacedoME, PegoM. Prevalence of isolated systolic hypertension in the population over 55 years old. Results from a national study. Rev Port Cardiol. 2007; 26: 11–18.
21.
FigueiredoD, AzevedoA, PereiraM, . Definition of hypertension: the impact of number of visits for blood pressure measurement. Rev Port Cardiol. 2009; 28: 775–783.
22.
ModestiPA, RapiS, BamoshmooshM, . Impact of one or two visits strategy on hypertension burden estimation in HYDY, a population-based cross-sectional study: implications for healthcare resource allocation decision making. BMJ Open. 2012; 0: e001062.
23.
BovetP, GervasoniJP, RossAG, . Assessing the prevalence of hypertension in populations: are we doing it right?J Hypertens. 2003; 21: 509–517.
24.
KearneyPM, WheltonM, ReynoldsK, . Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004; 22: 11–19.
25.
PereiraM, LunetN, AzevedoA, . Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009; 27: 963–975.
26.
PereiraM, CarreiraH, ValesC, . Trends in hypertension prevalence (1990-2005) and mean blood pressure (1975-2005) in Portugal: a systematic review. Blood Pressure. 2012; 21: 220–226.
27.
DanaeiG, FinucaneMM, LinJK, . National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet. 2011; 377: 568–577.
28.
LealJ, Luengo-FernandezR, GrayA, eds.European Cardiovascular Disease Statistics 2012. ed.Brussels: European Heart Network, Sophia Antipolis: European Society of Cardiology; 2012.
29.
Saúde DGd.Statistic Elements—General Health Information/2008. Saúde DGd, ed.Lisbon, Portugal: Direcção Geral de Saúde; 2010: 159.
30.
DanaeiG, FinucaneMM, LuY, . National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 27 million participants..Lancet. 2011; 378: 31–40.
31.
Gardete-CorreiaL, BoavidaJM, RaposoJF, . First diabetes prevalence study in Portugal: PREVADIAB study. Diabet Med. 2010; 27: 879–881.
32.
Cortez-DiasN, MartinsS, BeloA, . Prevalence, management and control of diabetes mellitus and associated risk factors in primary health care in Portugal. Rev Port Cardiol. 2010; 29: 509–537.
33.
WhitingDR, GuariguataL, WeilC, . IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011; 94: 311–321.
34.
SarnakMJ, LeveyAS, SchoolwerthAC, . Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003; 42: 1050–1065.
35.
de ZeeuwD, HillegeHL, de JongPE.The kidney, a cardiovascular risk marker, and a new target for therapy. Kidney Int Suppl. 2005: S25–S29.
36.
HillegeHL, FidlerV, DiercksGF, . Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777–1782.
37.
RuilopeL, KjeldsenSE, de la SierraA, . The kidney and cardiovascular risk-implications for management: a consensus statement from the European Society of Hypertension. Blood Pressure. 2007; 16: 72–79.
38.
VinhasJ, Gardete-CorreiaL, BoavidaJM, . Prevalence of chronic kidney disease and associated risk factors, and risk of end-stage renal disease: data from the PREVADIAB study. Nephron Clin Pract. 2011; 119: c35–c40.
39.
ZhangQL, RothenbacherD.Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008; 8: 117.
40.
GansevoortRT, de JongPE.The case for using albuminuria in staging chronic kidney disease. J Am Soc Nephrol. 2009; 20: 465–468.
41.
LeveyAS, de JongPE, CoreshJ, . The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011; 80: 17–28.
42.
HallanSI, MatsushitaK, SangY, . Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012; 308: 2349–2360.
43.
FoxCS, MatsushitaK, WoodwardM, . Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet. 2012; 380: 1662–1673.
44.
PoloniaJ, CarmonaJ, MendesE, . Prevalence of microalbuminuria in non-diabetic hypertensive patients attended by Portuguese GPs. Rev Port Cardiol. 2007; 26: 637–644.
45.
CostaJ, BorgesM, OliveiraE, . Incidence and prevalence of hypercholesterolemia in Portugal: a systemic review. Part II. Rev Port Cardiol. 2003; 22: 683–702.
46.
CostaJ, BorgesM, OliveiraE, . Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part I. Rev Port Cardiol. 2003; 22: 569–577.
47.
CostaJ, BorgesM, OliveiraE, . Incidence and prevalence of hypercholesterolemia in Portugal: a systematic review. Part III. Rev Port Cardiol. 2003; 22: 829–836.
48.
FiuzaM, Cortez-DiasN, MartinsS, . Metabolic syndrome in Portugal: prevalence and implications for cardiovascular risk—results from the VALSIM Study. Rev Port Cardiol. 2008; 27: 1495–1529.
49.
da SilvaPM, CardosoSM.Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS). Rev Port Cardiol. 2011; 30: 47–63.
50.
FarzadfarF, FinucaneMM, DanaeiG, . National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet. 2011; 377: 578–586.
51.
SantosAC, LopesC, BarrosH.Prevalence of metabolic syndrome in the city of Porto. Rev Port Cardiol. 2004; 23: 45–52.
52.
SardinhaLB, SantosDA, SilvaAM, . Prevalence of overweight, obesity, and abdominal obesity in a representative sample of Portuguese adults. PLoS One. 2012; 7: e47883.
53.
do CarmoI, Dos SantosO, CamolasJ, . Overweight and obesity in Portugal: national prevalence in 2003-2005. Obes Rev. 2008; 9: 11–19.
54.
MitchellGF, HwangSJ, VasanRS, . Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010; 121: 505–511.
55.
VlachopoulosC, AznaouridisK, StefanadisC.Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010; 55: 1318–1327.
56.
LaurentS, CockcroftJ, van BortelL, . Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006; 27: 2588–2605.
57.
ManciaG, FagardR, NarkiewiczK, . 2013ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013; 31: 1281–1357.
58.
Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and reference values’. Eur Heart J. 2010; 31: 2338–2350.
59.
PoloniaJ, MaldonadoJ, RamosR, . Estimation of salt intake by urinary sodium excretion in a Portuguese adult population and its relationship to arterial stiffness. Rev Port Cardiol. 2006; 25: 801–817.
60.
MaldonadoJ, PereiraT, PoloniaJ, . Arterial stiffness predicts cardiovascular outcome in a low-to-moderate cardiovascular risk population: the EDIVA (Estudo de DIstensibilidade VAscular) project. J Hypertens. 2011; 29: 669–675.
61.
PereiraT, MaldonadoJ, PoloniaJ, . A statistical definition of aortic pulse wave velocity normality in a Portuguese population: a subanalysis of the EDIVA project [Portuguese]. Rev Port Cardiol. 2011; 30: 691–698.
62.
Agabiti-RoseiE, ManciaG, O'RourkeMF, . Central blood pressure measurements and antihypertensive therapy: a consensus document. Hypertension. 2007; 50: 154–160.
63.
VlachopoulosC, AznaouridisK, O'RourkeMF, . Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010; 31: 1865–1871.
64.
RomanMJ, DevereuxRB, KizerJR, . Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007; 50: 197–203.
65.
RomanMJ, DevereuxRB, KizerJR, . High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study. J Am Coll Cardiol. 2009; 54: 1730–1734.
66.
BrietM, PierreB, LaurentS, . Arterial stiffness and pulse pressure in CKD and ESRD. Kidney Int. 2012; 82: 388–400.
67.
O'RourkeMF, SafarME.Relationship between aortic stiffening and microvascular disease in brain and kidney: cause and logic of therapy. Hypertension. 2005; 46: 200–204.
68.
NilssonPM, BoutouyrieP, CunhaP, . Early vascular ageing in translation: from laboratory investigations to clinical applications in cardiovascular prevention. J Hypertens. 2013; 31: 1517–1526.
69.
NilssonPM.Early vascular aging (EVA): consequences and prevention. Vasc Health Risk Manag. 2008; 4: 547–552.
70.
LakattaEG, LevyD.Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease. Circulation. 2003; 107: 139–146.
71.
LakattaEG.Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation. 2003; 107: 490–497.
NilssonPM, LurbeE, LaurentS.The early life origins of vascular ageing and cardiovascular risk: the EVA syndrome. J Hypertens. 2008; 26: 1049–1057.
74.
KotsisV, StabouliS, KarafillisI, . Early vascular aging and the role of central blood pressure. J Hypertens. 2011; 29: 1847–1853.
75.
GorelickPB, ScuteriA, BlackSE, . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42: 2672–2713.
76.
GorelickPB, WilliamM.Feinberg lecture: cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke. 2005; 36: 875–879.
InzitariD, PracucciG, PoggesiA, . Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (Leukoaraiosis and Disability) study cohort. BMJ. 2009; 339: b2477.
79.
PoggesiA, PantoniL, InzitariD, . 2001-2011: A decade of the LADIS (Leukoaraiosis And DISability) study: what have we learned about white matter changes and small-vessel disease?Cerebrovasc Dis. 2011; 32: 577–588.
80.
VerdelhoA, MadureiraS, FerroJM, . Differential impact of cerebral white matter changes, diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The LADIS study. J Neurol Neurosurg Psychiatry. 2007; 78: 1325–1330.
81.
NunesB, SilvaRD, CruzVT, . Prevalence and pattern of cognitive impairment in rural and urban populations from Northern Portugal. BMC Neurol. 2010; 10: 42.
82.
MaillardP, SeshadriS, BeiserA, . Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012; 11: 1039–1047.
83.
WaldsteinSR, RiceSC, ThayerJF, . Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension. 2008; 51: 99–104.
84.
ScuteriA, TesauroM, AppolloniS, . Arterial stiffness as an independent predictor of longitudinal changes in cognitive function in the older individual. J Hypertens. 2007; 25: 1035–1040.
85.
PaseMP, HerbertA, GrimaNA, . Arterial stiffness as a cause of cognitive decline and dementia: a systematic review and meta-analysis. Intern Med J. 2012; 42: 808–815.
86.
HenskensLH, KroonAA, van OostenbruggeRJ, . Increased aortic pulse wave velocity is associated with silent cerebral small-vessel disease in hypertensive patients. Hypertension. 2008; 52: 1120–1126.
